Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 15;14:5287–5301. doi: 10.2147/IJN.S203113

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Zhang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Effects of sCS NPs-HA on tumor growth, the injection dose of Cy3-labeled siRNA in all experimental groups was 0.16 mg siRNA/kg. (A) Tumors isolated from murine groups PBS, naked Cy3-labeled siRNA, sCS NPs, and sCS NPs-HA. The weight of tumors in the murine sCS NPs-HA group was significantly lower as compared with the PBS group. **P<0.01 (one-way ANOVA (and nonparametric) and t-tests), ns means not statistical significance. The tumor growth inhibition graph showed that the growth of subcutaneous tumor volume in the sCS NPs-RNA group was significantly inhibited. (B) The indices (weight ratios) of liver, kidneys, or spleen to the body weight for all groups (n≥3). There were no statistically significant differences between the control and any experimental groups, P>0.5 (one-way ANOVA (and nonparametric)). (C) Expression levels of the BCL2 protein in the tumors from mice, as determined by Western blotting and normalized to GAPDH expression. Data are presented as mean ± SD of three experiments. **P<0.01, ***P<0.001, ****P<0.0001 (one-way ANOVA (and nonparametric) and t-tests).